Generation Bio Co.

Public biopharma companies usually spend the week before the J.P. Morgan Healthcare Conference announcing new financings, partnerships and sometimes data so that they have compelling milestones to dis

Who: Roche Holding AG ’s Genentech, Inc. / GenEdit Inc. What: Genentech will partner with GenEdit to discover hydrophilic nanoparticles for the development of nucleic acid-based medicines for au

Recent private placements and follow-on financings show that despite public company valuations being down across the board during the past two years, it still is possible to drum up investor support f

Generation Bio Co. ’s platform technology got a big stamp of approval thanks to a deal with Moderna, Inc. that grants Moderna the option to license Generation Bio’s lipid nanoparticle (LNP) and DNA